Atea Pharmaceuticals (AVIR) Return on Capital Employed (2020 - 2026)
Atea Pharmaceuticals (AVIR) recorded quarterly Return on Capital Employed of 73.65% in Q1 2026, down 17.79% quarter-over-quarter from 62.52% in Q4 2025, and down 3598.0% on a YoY basis from 2.11% in Q1 2025.
Atea Pharmaceuticals (AVIR) Return on Capital Employed (2020 - 2026) Analysis & Trends
Atea Pharmaceuticals' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 73.65% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3598.0% year-over-year to 73.65%; the TTM figure through Mar 2026 stood at 73.65% (down 3598.0% YoY), while the FY2025 annual figure was 51.66%, down 1392.0% from the prior year.
- Return on Capital Employed was 73.65% for Q1 2026 at Atea Pharmaceuticals, down from 62.52% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 9.15% in Q1 2022 to a low of 73.65% in Q1 2026.
- Historically, Return on Capital Employed has averaged 30.67% across 5 years, with a median of 36.12% in 2024.
- Biggest YoY gain for Return on Capital Employed was 519 bps in 2022; the steepest drop was 3827 bps in 2022.
- A 5-year view of Return on Capital Employed shows it stood at 19.85% in 2022, then slumped by 45 bps to 28.84% in 2023, then plunged by 46 bps to 42.02% in 2024, then slumped by 49 bps to 62.52% in 2025, then dropped by 18 bps to 73.65% in 2026.
- The last three Return on Capital Employed figures came in at 73.65% (Q1 2026), 62.52% (Q4 2025), and 47.53% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Atea Pharmaceuticals | 347.28 Mn | 347.28 Mn | - | -73.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.65% |
| Dec 31, 2025 | -62.52% |
| Sep 30, 2025 | -47.53% |
| Jun 30, 2025 | -39.58% |
| Mar 31, 2025 | -37.67% |
| Dec 31, 2024 | -42.02% |
| Sep 30, 2024 | -42.17% |
| Jun 30, 2024 | -40.40% |
| Mar 31, 2024 | -36.12% |
| Dec 31, 2023 | -28.84% |
| Sep 30, 2023 | -26.33% |
| Jun 30, 2023 | -21.59% |
| Mar 31, 2023 | -20.32% |
| Dec 31, 2022 | -19.85% |
| Sep 30, 2022 | 4.51% |
| Jun 30, 2022 | 3.61% |
| Mar 31, 2022 | 9.15% |
| Dec 31, 2021 | 18.42% |
| Sep 30, 2021 | 6.35% |
| Jun 30, 2021 | 7.27% |